Oricell Therapeutics Co., Ltd

About Oricell Therapeutics Co., Ltd

Oricell Therapeutics (原启生物) aims to be a global leader in innovation-driven development of novel cancer immunotherapies. The company is dedicated to developing innovative, clinically valuable cell therapies for unmet clinical needs in cancers such as liver cancer, multiple myeloma, gastric cancer, pancreatic cancer, cholangiocarcinoma, and ovarian cancer, providing safer and more effective treatment solutions for patients and doctors.

Products & Services

OriCAR-017:A GPRC5D-targeted CAR-T therapy for relapsed or refractory multiple myeloma. Received US IND approval in December 2023, NMPA IND approval in August 2023, FDA Orphan Drug Designation in October 2022, with follow-up data published in The Lancet Haematology and clinical data presented at ASCO and EHA 2022.

Ori-C101:A GPC3-targeted CAR-T therapy for advanced liver cancer. Received NMPA IND approval in September 2022, with clinical results announced at ASCO 2021.

Specialties

Cancer Immunotherapy Cell Therapy CAR-T Therapy Antibody Screening and Optimization (OriAb Platform) Tumor Microenvironment Improvement (OriCAR Platform) Clinical Development for Unmet Needs in Oncology

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Pre-IPO T: - FT: Pre-IPO	A: 110000000 MR: - FA: $110 million FAN: 110000000	D: 2026-04-09 FD: 2026-04-09	10 investors
2	RT: Series C T: - FT: Series C	A: 70000000 MR: - FA: $70M FAN: 70000000	D: 2026-01-12 FD: 2026-01-12	8 investors
3	RT: Series B1 T: - FT: Series B1	A: 45000000 MR: - FA: $45M FAN: 45000000	D: 2023-02-28 FD: 2023-02-28	4 investors

Pre-IPO Latest

2026-04-09

$110.0M

10 investors (Pro only)

Series C 2026-01-12

$70.0M

Series B1 2023-02-28

$45.0M

View 2 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

K

Kenneth C. Anderson

Professor

S

Shaji Kumar

Professor

Recent News